Clinical Trials | May 21, 2024
Modular ATP study of the mCRM System meets primary safety and efficacy endpoints
Additional data from APPRAISE ATP trial reinforce modular therapy approach
Additional data from APPRAISE ATP trial reinforce modular therapy approach
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Subscribe To Our Newsletter & Stay Updated
